Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Wang Y, Hu Q, Madri J, Rollins S, Chodera A, Matis L. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 8563-8568. PMID: 8710910, PMCID: PMC38712, DOI: 10.1073/pnas.93.16.8563.Peer-Reviewed Original ResearchConceptsNZB/W F1 miceNZB/WF1 miceLupus-like autoimmune diseaseW F1 miceF1 miceAutoimmune diseasesNew Zealand Black x New Zealand White F1 miceFemale NZB/W F1 miceFemale NZB/WF1 miceHuman systemic lupus erythematosusMonoclonal antibodiesCourse of glomerulonephritisSystemic lupus erythematosusImmune complex glomerulonephritisSystemic complement activationWhite F1 miceImmune complex nephritisMonths of ageSevere glomerulonephritisAntinuclear antibodiesComplement component C5Continuous therapyAutoimmune syndromeLupus erythematosusRenal disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply